Feng Z.

• Dedicated and experienced pharmaceutical researcher focusing on neurology and immunology space with a decade of expertise in medicinal chemistry, drug design, synthetic organic chemistry and capabilities also including multi-step synthesis (up to 29 steps) and methodology development on transition metals (Pd, Rh, Cu etc.) catalysis. • Proven track record in conducting innovative research, analyzing complex data sets, and contributing to the advancement of multiple discovery programs (> 10 projects), publishing findings in reputable scientific journals, ORCID: https://orcid.org/0009-0003-8017-8430. • Co-inventor of the clinical candidate FTX-6058, Pociredir (PCT/US2020/022724) and co-authored 18 peer-reviewed high-level scientific publications, 1 book chapter (C-H bond activation reactions in aqueous medium) • Pharmaceutical career started since 2015, conducting research in a broad range of fields and modalities, spanning small molecule drug discovery, PROTACs degraders, macrocyclic peptide therapeutics and peptide platform optimizations, nucleic acid therapeutics; engaging in multidisciplinary preclinic discovery and development teams at all stages of discovery process to identify clinic candidates. * Conceive, design, and execute medicinal chemistry initiatives utilizing medicinal chemistry knowledge across multiple project phases, hit generation, lead identification and optimization, ADMET properties optimization, pharmacokinetics, all within the context of a target pharmaceutical product profile. * Extensive hands-on experience in diverse organic transformations, including wet-lab experience of synthesizing variety of heterocycles, spirocycles, macrocycles, PROTACS, peptides and nucleoside derivatives exhibiting important biological activities. * Work with DEL team for libraries design and H2L follow-up, developed solid phase organic synthesis techniques. * Collaborate with cross-functional teams including biologists, DMPK scientists, pharmacologists etc.; managing the synthetic efforts conducted at CRO partners.